Previous 10 | Next 10 |
Gainers: Regional Health Properties (NYSEMKT: RHE ) +183% . Moleculin Biotech (NASDAQ: MBRX ) +51% . The KeyW Holding (NASDAQ: KEYW ) +43% . Key Energy Services (NYSE: KEG ) +32% . Iconix Brand Group (NASDAQ: ICON ) +25% . Lantronix (NASDAQ: LTRX ) +15% . Denbury Resources (NYS...
Regional Health Properties (NYSEMKT: RHE ) +140% . More news on: Regional Health Properties, Inc., The KeyW Holding Corporation, Moleculin Biotech, Inc., Stocks on the move, Read more ...
HOUSTON , April 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it will host a conference cal...
The FDA approves Moleculin Biotech's (NASDAQ: MBRX ) request for Fast Track Designation of Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia ("AML"). More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...
April 18, 2019 Palm Beach, FL – April 18, 2019 – A recent headline from a report released by Friends of Cancer Research, made the following eye-opening statement: “ ONE OF THE BIGGEST TREATMENT BREAKTHROUGHS IN THE PAST FIVE YEARS WASN’T A DRUG, BUT A LAW....
HOUSTON , April 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the U.S. Food and Drug Administra...
April 17, 2019 Palm Beach, FL – April 17, 2019 – The American Association for Cancer Research (AARC) recently released an article that interviewed Nobel Laureate, Fellow of the AACR Academy, and immunotherapy pioneer James P. Allison, PhD and AACR President-elec...
HOUSTON , April 17, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its ongoing sponsored resea...
April 11, 2019 Palm Beach, FL – April 11, 2019 – Every business or industry strives to improve quality, reduce costs and improve their products time to market. This, surprisingly, is true for the biotechnology industry as well. Usually regulations increase costs and create ...
HOUSTON , April 11, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has entered into an agreement...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial PR Newswire Based on an encouraging discussion in the End of Phase 1B /2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for po...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...